Loading
AT
Akcea Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by IONIS PHARMACEUTICALS INC, was filed 14 Oct 2020.
Akcea Therapeutics, Inc.: what insiders have been doing
Akcea Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Akcea Therapeutics, Inc. The previous disclosure was published on 14 October 2020.
Since 2017, the database holds 3 purchases and 14 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
70
Thresholds
n/a
Buy Volume
€511M
3 ops. · all time
Sell Volume
€3M
14 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended December 2019 · cache
Income statement
Revenue435.5M
Net income36.3M8.3% margin
Last declaration on 14 October 2020
Declarations70 total
21,237,715 shares@ US$18.15100.0% of flowCommon StockSEC:0000899243-20-028167:0
Canonical exit: 8 Jan 2021 (T+90)
242,978 shares@ US$18.1593.7% of flowCommon StockSEC:0001209191-20-054613:0
37,500 shares@ US$18.15100.0% of flowCommon StockSEC:0001209191-20-054614:0
66,800 shares@ US$18.15100.0% of flowCommon StockSEC:0001209191-20-054615:0
52,012 shares@ US$18.1597.6% of flowCommon StockSEC:0001209191-20-054616:0
26,532 shares@ US$18.1597.3% of flowCommon StockSEC:0001209191-20-054618:0
50,000 shares@ US$18.15100.0% of flowCommon StockSEC:0001209191-20-054622:0
319 shares@ US$18.121.2% of flowCommon StockSEC:0001209191-20-051894:0
720 shares@ US$18.121.4% of flowCommon StockSEC:0001209191-20-051891:0
8,709 shares@ US$18.123.4% of flowCommon StockSEC:0001209191-20-051888:0
1,104 shares@ US$14.400.3% of flowCommon StockSEC:0001209191-20-049120:0
263 shares@ US$12.500.7% of flowCommon StockSEC:0001209191-20-043062:0
37,500 shares0Common StockSEC:0001209191-20-042203:0
50,000 shares0Common StockSEC:0001209191-20-030621:0
12,500 shares0Common StockSEC:0001209191-20-024511:0
60,000 shares0Common StockSEC:0001209191-20-021951:0
3,198 shares@ US$11.75100.0% of flowCommon StockSEC:0001209191-20-021120:0
9,417 shares@ US$11.752.6% of flowCommon StockSEC:0001209191-20-021118:0
779 shares@ US$11.751.0% of flowCommon StockSEC:0001209191-20-021122:0
335 shares@ US$11.760.9% of flowCommon StockSEC:0001209191-20-021123:0
16,800 shares0Common StockSEC:0001209191-20-020642:0
16,800 shares0Common StockSEC:0001209191-20-020647:0
3,780 shares0Common StockSEC:0001209191-20-020637:0
55,200 shares0Common StockSEC:0001209191-20-020632:0
16,800 shares0Common StockSEC:0001209191-20-020643:0
25 of 70 declarations
About Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare genetic diseases. It specializes in treatments based on oligonucleotide technology.
